Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Notice of Results

14th Apr 2015 07:00

RNS Number : 0824K
Lifeline Scientific, Inc
14 April 2015
 

 

Lifeline Scientific, Inc.

("Lifeline" or the "Company")

 

Notice of Results

Investor Results Presentations

 

Lifeline Scientific (AIM: LSIC), the transplantation technology company, will announce its preliminary results for the year ended 31 December 2014 on Monday 27 April 2015.

 

Analyst presentation

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London, EC3V 9HD at 12.00pm on Monday 27 April 2015.

 

Investor presentation

A briefing for all investors will take place on Tuesday 28 April 2015 at Rocket, 6 Adams Court, Old Broad Street, London EC2N 1DX from 4:30pm for a 4.45pm start, and will be followed by drinks and canapés.

 

If you would like to register to attend either presentation, or require further information, please contact Lianne Cawthorne at Walbrook PR on 020 7933 8780 or email [email protected].

 

 

 For further information:

 

Lifeline Scientific, Inc.

www.lifeline-scientific.com

David Kravitz, CEO

Tel: +1 847 294 0300

Lisa Kieres, CFO

Tel: +1 847 294 0300

 

 

Panmure Gordon (UK) Limited

Tel: +44 (0)20 7886 2500

Freddy Crossley (Corporate Finance)

 

Maisie Atkinson (Corporate Broking)

 

 

 

Walbrook PR Limited

Tel: +44 (0) 20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893

Mike Wort

Mob: +44 (0)7900 608 002

 

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product, LifePort Kidney Transporter, is the global market-leading medical device for hypothermic machine preservation of donor kidneys. LifePorts and novel solutions designed for preservation of other organs are in development, with LifePort Liver Transporter next in line for commercial launch. For more information please visit www.lifeline-scientific.com

 

About LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to help improve kidney preservation, evaluation and transport prior to transplantation. It has been widely studied in clinical trials throughout the world and is the standard of care for machine preservation of kidneys. Employed by surgeons in over 185 leading transplant programmes in 27 countries, LifePorts have successfully preserved over 47,000 kidneys indicated for clinical transplant. For more information please visit www.organ-recovery.com

 

About LifePort Liver Transporter

LifePort Liver Transporter is modeled upon the clinically proven technology platform of LifePort Kidney Transporter and the Company's early HMP prototype successfully used in clinical transplant studies by surgeons at New York-Presbyterian Hospital/Columbia University Medical Center. LifePort Liver Transporter and the Company's proprietary machine preservation solution, Vasosol®, are in the process of US and European regulatory registrations. The system is designed to help improve outcomes in liver transplantation by enabling the clinical use of hypothermic machine perfusion, and has been developed in consultation with clinical and research teams specializing in liver transplantation at Columbia University Medical Center and the University of Chicago. The system employs a rugged, streamlined ergonomic design for ease of use and transportability from donor bedside to recipient operating room. For more information please visit: http://www.organ-recovery.com/pipeline.php

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORBRGDSDGBBGUX

Related Shares:

LSIC.L
FTSE 100 Latest
Value7,913.25
Change233.77